FDA awards breakthrough status to Celladon's gene therapy

04/10/2014 | Xconomy

Celladon's advanced heart failure drug Mydicar has received breakthrough-therapy designation from the FDA and is the first gene therapy to receive the designation. The designation was based on data from a clinical trial that showed Mydicar reduced heart failure-related hospitalizations by 88% in patients receiving the highest dose of the drug.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX